News
-
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
Jaguar Health announces success of crofelemer powder for oral solution in treating infant patient with congenital sodium diarrhea. Plans for NDA in 2027 for MVID treatment -
-
-
COMMUNIQUÉ DE PRESSE
Jaguar Health Provides Update Regarding Special Stock Dividend
Jaguar Health, Inc. provides update on special stock dividend payout and ex-dividend date for Series R Convertible Preferred Stock. CEO Lisa Conte comments on company's strategic focus and development program for oral crofelemer -